EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)

Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News

Country: Germany · Primary market: Germany · EQS NID: 2036955

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch
Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)

27.11.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Berlin, 27 November 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand^®, by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand^® in routine clinical applications throughout the European Economic Area (EEA).

Theralugand^® provides high-purity Lutetium-177 produced in compliance with GMP standards with specifications designed for the labelling of therapeutic radiopharmaceuticals. The approval unlocks its potential to support innovative cancer therapies such as those targeting neuroendocrine tumors and metastatic prostate cancer. The previous, GMP-certified Lutetium-177 was limited to investigational use in clinical studies.

Eckert & Ziegler collaborates with pharmaceutical companies worldwide to develop and manufacture Lutetium-177-based radiopharmaceuticals, furthering the reach of targeted radiotherapies for the global market. Through these partnerships, Eckert & Ziegler plays a vital role in providing innovative cancer treatments.

“We are excited to achieve the EC approval for Theralugand^®, a critical step in making innovative treatment options widely available for clinical applications across Europe,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This accomplishment reflects our dedication to the production and distribution of reliable therapeutic radiopharmaceuticals.”

Eckert & Ziegler is gearing up to meet the rising global demand for Lutetium-177 by actively expanding production capacities, ensuring a stable supply of this critical therapeutic radioisotope.

About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

27.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Eckert & Ziegler SE
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	+49 30 941084-138
Fax:	+49 30 941084-0
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX, TecDax,
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	2036955


End of News	EQS News Service

2036955 27.11.2024 CET/CEST

More Research

Company related KPIs

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
	2018	2019	2020	2021	2022	2023	2024e
Sales¹	168,71	178,49	176,14	180,44	222,26	246,09	290,00
EBITDA^1,2	32,14	43,13	44,64	57,04	55,52	58,83	0,00
EBITDA-Margin³	19,05	24,16	25,34	31,61	24,98	23,91	0,00
EBIT^1,4	23,39	32,06	33,69	47,45	44,54	45,45	60,00
EBIT-Margin⁵	13,86	17,96	19,13	26,30	20,04	18,47	20,69
Net Profit (Loss)¹	16,89	22,48	23,11	34,66	29,75	26,77	0,00
Net-Margin⁶	10,01	12,60	13,12	19,21	13,39	10,88	0,00
Cashflow^1,7	21,21	40,43	36,79	33,86	34,30	47,40	0,00
Earnings per share⁸	0,78	1,07	1,11	1,66	1,41	1,26	1,54
Dividend per share⁸	0,30	0,42	0,45	0,50	0,50	0,05	0,50

Quelle: boersengefluester.de and Company information

Explanation

¹ in Mio. Euro; ² EBITDA = Earnings before interest, taxes, depreciation and amortisation; ³ EBITDA in relation to sales; ⁴ EBIT = Earnings before interest and taxes; ⁵ EBIT in relation to sales; ⁶ Net profit (-loss) in relation to sales; ⁷ Cashflow from operations; ⁸ in Euro; Source: boersengefluester.de

Auditor: Forvis Mazars

Company Snapshot

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Eckert & Ziegler
WKN	ISIN	Legal Type	Marketcap	IPO	Recommendation	Plus Code
565970	DE0005659700	SE	943,84 Mio €	25.05.1999	Halten	9F4MJGG3+WR

* * *

PE 2025e	PE 10Y-Ø	BGFL-Ratio	Shiller-PE	PB	PCF	KUV
27,52	26,29	1,05	49,04	4,27	19,91	3,84

Dividends

Dividend '2022 in €	Dividend '2023 in €	Dividend '2024e in €	Div.-Yield '2024e in %
0,50	0,05	0,50	1,12%

Financial calendar

Annual General Meeting	Q1-figures	Q2-figures	Q3-figures	Annual press conference
18.06.2025	13.05.2025	08.08.2025	14.11.2024	27.03.2025

Performance

Distance 60-days-line	Distance 200-days-line	Performance YtD	Performance 52 weeks	IPO	Last Price (EoD) +0,41% 44,58 € ATH 141,40 €
+5,41%	+14,32%	+21,44%	+24,09%	+675,30%	Last Price (EoD) +0,41% 44,58 € ATH 141,40 €

LEI: 391200EUDABLUKXCKG48

Social media-channel

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)

Quick Links

Network

Partner

Contact

EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)

Would you like to see fewer adverts? Simply register for a user account. Registration is free and significantly reduces the number of adverts.

Quick Links

Network

Partner

Contact